Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
All News
Article
Article
Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients who will require chronic glucocorticoids.
Article
Dr. Jack Cush reviews the journal articles and regulatory announcements from this past week on RheumNow, including: two crystals in one joint, twice the cryptococcus risk in JAKs; Myositis and Scleroderma; and Sjögren’s plus early damage = >> 2 fold risk lymphoma. Double trouble week on the RheumNow podcast.
Grappa Symposium: Leung Obesity in PsA - done deal
@RheumNow #APLAR2026 https://t.co/3YQT4kiPer
sheila
Tweet
An important and relevant reminder from @rheumarhyme on AI use
@RheumNow #APLAR2026 https://t.co/7Ratb6aQOD
sheila
Tweet
AI can be helpful in manuscript creation
As the author:
> always verify the draft - allow time to check
> take full responsibility of the content - review and revise the final manuscript
@RheumNow #APLAR2026 https://t.co/cQsEtDc7z1
The @RheumNow crew together at #APLAR2026 https://t.co/9YizHIFprF
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic https://t.co/TPqPKP5MRl
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
Listen to leading rheumatology and dermatology experts for an engaging discussion on the evolving landscape of Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE). https://t.co/lJOzeR81AS
ACR Convergence 2026 is almost here. Whether you’re attending in person or following from afar, RheumNow will bring you the research, clinical updates and expert insights you need to know.
Join us for #ACR26 coverage beginning November 7th at https://t.co/ofGKCCNQnE.
#ACR26 https://t.co/lMJSrkxMlN
Excites to report on #APLAR26 in Seoul, S. Korea for @RheumNow along with Drs. @RHEUMarampa and Peter Nash https://t.co/QImSxM7Izi
Saag GIOP guidelines
APLAR Seoul 2026 #GIOP #RheumNow https://t.co/HIEHcaQDeO
Oswestry Disability Index in axSpA (n=107, India): a patient-reported, low-cost, quick tool that tracked closely with BASDAI (r=0.77), BASFI (r=0.80) and ASDAS-CRP (r=0.79). Could help where rheumatologists are scarce. P#478 #APLAR26 @RheumNow https://t.co/teoMtnM3Gl
A positive SI joint MRI alone is not specific for axSpA: ASAS MRI-positive in 23.4% of healthy volunteers, 12.5% of runners and 57.1% of postpartum back pain, vs 91.5% of axSpA. Without clinical context, overdiagnosis is a risk. AYR session #APLAR26 @RheumNow https://t.co/U3wFOm01B4
2026 BSR Guideline for the Treatment of Polymyalgia Rheumatica
Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines.
https://t.co/o1Y1a13WIG https://t.co/W9jNGfMgP7
2024 web survey of German rheumatologists on CAR-T & T-cell redirecting therapies. 95% willing to refer pts to specialized centers; but 5% (most severe) are suitable for TCRT. Barriers cited: high costs (82%), limited experience (65%) & limited # appropriate Pts (35%). 4.86/10 https://t.co/o62uRVsIC7
Mark your calendar: RheumNow is covering ACR Convergence 2026, beginning November 7th!
Follow along for clinical trial highlights, expert perspectives, daily faculty recaps, livestreams and more.
Visit https://t.co/ofGKCCNQnE for the latest coverage.
#ACR26 #Rheumatology https://t.co/5p5UxMLu51
Comorbidity management is subpar in Rheum. Surveys of 2213 inflamm rheum Dz pts & 140 rheumatologists. Rheums think theyre OK (71-92%) screening (HTN, OP, vaccines, CA), but pts say NOT (12=33%).Rheums agree they have no structured comorbidity screening in place (time 91%, https://t.co/mqcptziRdw
RheumNow Live 2027 registration is NOW OPEN.
GLP-1s in your clinic. CAR-T in lupus. Rheumatology experts vs. AI, with your vote.
Jan. 30–31 | Onsite + virtual
Early Bird Pricing through 12/15/2026.
See the agenda. Register: https://t.co/zYYC2350tE https://t.co/QeSxDPlIpv


